Compare HRMY & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | SEMR |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | 2021 |
| Metric | HRMY | SEMR |
|---|---|---|
| Price | $27.07 | $11.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $46.70 | $10.00 |
| AVG Volume (30 Days) | 630.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | $443,644,000.00 |
| Revenue This Year | $19.75 | $16.85 |
| Revenue Next Year | $12.88 | $14.35 |
| P/E Ratio | $9.79 | ★ N/A |
| Revenue Growth | ★ 21.51 | 17.74 |
| 52 Week Low | $25.52 | $6.56 |
| 52 Week High | $40.87 | $11.95 |
| Indicator | HRMY | SEMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 67.70 |
| Support Level | $25.71 | $11.90 |
| Resistance Level | $28.99 | N/A |
| Average True Range (ATR) | 0.72 | 0.02 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 28.44 | 73.21 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
SEMrush Holdings Inc offers an online visibility management software-as-a-service (SaaS) platform enabling its clients globally to identify and reach the right audience for their content. The platform utilizes data and intelligence at the core, surrounded by AI-powered interconnected hubs to provide customers with key data, helping them understand trends and derive actionable insights to improve their websites and social media pages, and distribute relevant content to their targeted customers across a variety of digital channels. The company generates nearly all of its revenue from subscriptions to its online visibility management SaaS platform under a SaaS model. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other regions.